Tomi Environmental Earnings Call Balances Growth and Risk

Tomi Environmental Solutions, Inc. ((TOMZ)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tomi Environmental Solutions’ latest earnings call struck a cautiously optimistic tone as management highlighted accelerating revenue, surging applicator adoption, and tighter cost control, even as widening losses, thin liquidity, and rising short-term liabilities weighed on the outlook. Investors heard a story of operational momentum constrained by balance-sheet fragility, with the proposed Carbonium Core merger offering potential upside but adding fresh execution risk.

Revenue Growth Shows Momentum

Tomi reported Q1 2026 revenue of $1.6 million, a 5% increase year over year, but more notably a 67% jump from Q4 2025, underscoring strong sequential momentum. Management framed the quarter as evidence that the company’s commercial strategy is gaining traction, though they acknowledged that absolute scale remains modest and results can still be lumpy.

Applicator Sales Surge Fuels Razor-Blade Model

Applicator sales in Q1 2026 exceeded total applicator sales for all of 2025, representing a 139% year-over-year increase and signaling rapid adoption of Tomi’s consumable-driven model. This surge is critical because each installed applicator anchors recurring BIT Solution consumable demand, creating a higher-margin, razor-and-blade style revenue stream over time.

BIT Solution Consumables Support Recurring Revenue

BIT Solution consumable sales have grown around 21% annually since 2024 and remained above 2025 levels in Q1 2026, reinforcing the shift toward recurring revenue. Management emphasized that as consumables and applicators scale, they should underpin margin recovery and reduce the company’s dependence on episodic, project-based work.

Costs Fall and Operating Cash Turns Positive

Total operating expenses fell 15% versus Q1 2025, reflecting tighter discipline around spending and headcount. As a result, Tomi generated positive operating cash flow of $296,000 in the quarter, a $572,000 improvement year over year, giving the company some breathing room despite a larger bottom-line loss.

Backlog and Pipeline Expand

Backlog climbed from $1.6 million at year-end 2025 to $2.2 million at the end of Q1 2026, a roughly $500,000 increase that points to solid near-term visibility. Beyond backlog, management cited an integration pipeline of $4 million across 14 customers and a broader sales pipeline of $22 million to $33 million, with about $9 million labeled active and approved for potential 2026 purchases.

Large Recurring Contract Adds Visibility

The company secured annual purchase orders totaling 440,000 units for recurring decontamination services from a leading global medical technology customer, to be delivered via quarterly professional IHP services. Management highlighted this agreement as a marquee, high-margin, repeatable revenue stream that validates Tomi’s technology and supports long-term revenue stability.

Regulatory Wins Open European Doors

On the regulatory front, Tomi received authorization from the U.K. Health & Safety Executive covering Great Britain and Northern Ireland, plus Dutch product authorization as its first EU member-state approval. The company also reported notifications of approvals in Germany, Belgium, Denmark, and Hungary, collectively opening broader access to European markets and supporting future growth.

Strategic Commercial Wins and Case Studies

Commercial traction included a SteraMist hybrid installation at a private East Coast research university, a follow-on award that demonstrates customer satisfaction and repeat demand. Tomi also sold a custom engineered system in the U.K. integrated into Total Clean Air’s platform, named it a preferred European partner, and highlighted a food-safety case study where an egg producer cut sanitization testing costs by up to 95%.

Carbonium Core LOI Signals Strategic Pivot

Tomi signed a nonbinding letter of intent to merge with Carbonium Core, a nuclear-grade graphite producer, under which Carbonium would become a subsidiary and its holders receive nearly 20% of Tomi’s stock plus convertible preferred securities implying a $120 million enterprise value. Management framed the deal as a diversification play, but investors were reminded the agreement is early-stage, subject to due diligence and approvals, and could involve substantial dilution and future capital needs.

Gross Margin Compression Clouds Profit Path

Gross profit fell to $832,000 in Q1 2026 from $952,000 a year earlier, with gross margin around 50% as management leaned on strategic price discounts and a heavier mix of lower-margin equipment sales. While executives described the discounting as temporary and aimed at seeding future consumable demand, they conceded that the pace of margin recovery remains uncertain if competitive pressures keep promotions in place.

Service Revenue Declines on Project Timing

Service revenue decreased by $234,000, a 41% year-over-year drop that management attributed largely to timing of decontamination project completions and engagements. The company portrayed this as a temporary dip rather than a structural decline, but the shortfall underscored ongoing revenue variability and dependence on large, sometimes irregular projects.

Net Loss Widens and Deficit Deepens

Net loss expanded to $811,000, or $0.04 per share, in Q1 2026 compared with a $256,000 loss, or $0.01 per share, a year earlier, reflecting margin compression and the company’s still-limited scale. Tomi’s accumulated deficit grew to $58.9 million, a reminder that the business has yet to demonstrate sustained profitability despite recent operating improvements.

Liquidity Tightens and Working Capital Shrinks

The balance sheet remains a key risk, with cash ending the quarter at $280,000 and working capital at roughly $394,000, down from $88,000 and $1.0 million respectively at year-end 2025. Working capital shrank by about $630,000, driven partly by the net loss, leaving the company sensitive to any delays in collecting receivables or converting backlog into cash.

Short-Term Obligations and Modest Capital Raise

Accounts payable and accrued expenses increased by $993,000 while deferred revenue rose by $177,000, signaling rising short-term obligations and customer deposits that will require execution and cash outflows. Tomi raised just $149,000 in gross proceeds in Q1 via an equity line issuance of 336,147 shares, a limited capital injection relative to its expanding commitments and strategic ambitions.

Scale and Margin Recovery Uncertainty

Despite attractive percentage growth, Tomi’s absolute revenue and cash levels remain small, with Q1 sales of $1.6 million and only $280,000 in cash at quarter-end, leaving little room for missteps. Management insisted that discount-driven margin pressure should ease as the mix shifts toward higher-margin consumables, but acknowledged that ongoing discounting or slow adoption could prolong the recovery.

Carbonium Deal Execution Risks

The proposed Carbonium Core transaction carries notable uncertainty because the LOI is nonbinding and contingent on due diligence, definitive agreements, and shareholder approval. Management discussed potential dilution, with pro forma share counts possibly rising into the low 30 million range under certain conversion scenarios, and flagged that Carbonium may require additional capital, layering financing risk on top of execution risk.

Guidance and Outlook Emphasize Growth and Profit Target

Looking ahead, Tomi guided to continued revenue growth through 2026 and into 2027, with margin recovery driven by scaling BIT Solution consumables and applicator sales, and reaffirmed its ambition to reach profitability this year despite current losses. Management pointed to operating expense cuts, positive operating cash flow, a $2.2 million backlog, a $4 million integration pipeline, and a $22 million to $33 million sales pipeline as support for that outlook, while indicating plans to advance the Carbonium LOI and bolster the balance sheet via its equity line and other financing sources.

Tomi’s earnings call painted a story of a company gaining commercial traction and regulatory footholds while still navigating a fragile financial position and a complex strategic pivot. For investors, the appeal lies in the recurring revenue potential of consumables and large contracts, but the success of the Carbonium transaction, margin recovery, and near-term funding efforts will likely determine whether the current momentum translates into sustainable shareholder value.